Anti-Soluble TNF Receptor I + Fc Fragment antibody [EPR26198-14]

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

The Soluble TNF Receptor I + Fc Fragment also known as TNFRSF1A-Fc is a recombinant fusion protein with an approximate mass of 75 kDa. Mechanically this fusion protein acts by binding to tumor necrosis factor-alpha (TNF-α) inhibiting its activity and preventing interactions with cell surface TNF receptors. Soluble TNF Receptor I + Fc Fragment keeps the TNF-α activity in check by acting as a decoy receptor. It is expressed in various cells including immune cells and endothelial cells allowing it to modulate inflammatory responses effectively.

Biological function summary

The Soluble TNF Receptor I + Fc Fragment helps regulate immune and inflammatory responses. It functions by blocking the pro-inflammatory effects of TNF-α an element pivotal in the inflammatory process. By neutralizing TNF-α it prevents the recruitment and activation of immune cells and cytokines. This protein does not function alone; it works within larger protein complexes to execute its role in cellular communication and signal transduction.

Pathways

This fusion protein plays a significant role in the NF-κB and apoptosis signal pathways. Within these pathways TNF-α is an important mediator whose activity is moderated by the presence of the Soluble TNF Receptor I + Fc Fragment. By inhibiting TNF-induced activation of NF-κB the fusion protein can influence processes related to cell survival and death. It is closely related to proteins such as IκB (inhibitor of NF-κB) showing how its activity can have downstream effects on a variety of signaling processes.

Associated diseases and disorders

Soluble TNF Receptor I + Fc Fragment is used therapeutically in conditions like rheumatoid arthritis and inflammatory bowel disease. These disorders involve high levels of TNF-α which contribute to excessive inflammatory responses. The fusion protein helps mitigate such conditions by decreasing the TNF-α activity which in turn lowers inflammation. Through these actions this target is also indirectly connected to the regulatory proteins involved in these disorders like interleukin-6 (IL-6) which can also influence the inflammatory process.